Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Sana Biotechnology, Inc.NASDAQ: SANA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 802.4% from a year ago
Other current liabilities stood at $58.94M at the end of Q1 FY2026, up 802.4% from a year earlier and up 13.5% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.
Context
- Other current liabilities amounted to 15.8% of total assets at the end of Q1 FY2026, up 14.3 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +802.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 51.93M USD
- Year-over-year change
- +17209.3%
- 4-year CAGR
- -8.7%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.93M | +17209.3% |
| FY2024 | 2024-12-31 | 300K | -98.7% |
| FY2023 | 2023-12-31 | 23.46M | -69.4% |
| FY2022 | 2022-12-31 | 76.59M | +2.6% |
| FY2021 | 2021-12-31 | 74.63M | — |
Other Current Liabilities vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's Mar 2026 other current liabilities of $58.94M is the 2nd highest of the 11 companies compared; the peer median is $6.4M.
- Its year-over-year change of +802.4% is the highest of 9, against a peer median of -30.5%.
- Other current liabilities amounts to 15.8% of total assets for SANA, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $122.28M | +65.2% | +15.3% | 4.8% | |
| Mar 2026 | $58.94M | +802.4% | -12.2% | 15.8% | |
| Mar 2026 | $14.98M | — | -17.0% | 3.8% | |
| Jun 2026 | $12.18M | -31.2% | -9.9% | 0.9% | |
| Mar 2026 | $9.32M | -5.3% | +1.9% | 1.2% | |
| Mar 2026 | $8.45M | -29.8% | -40.5% | 3.0% | |
| Mar 2026 | $4.34M | +55.4% | +77.6% | 1.1% | |
| Mar 2026 | $2M | -34.8% | -36.7% | 1.4% | |
| Mar 2026 | $1.94M | -37.5% | +6.0% | 0.6% | |
| Mar 2026 | $1.34M | -39.0% | -60.4% | 6.7% | |
| Sep 2026 | $1.1M | — | -75.4% | 0.1% | |
| Peer median (excluding SANA) | $6.4M | -30.5% | -13.5% | 1.3% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 253.03M | 176.77M | 133.52M | 127.57M | 71.87M |
| Short-term Investments | 297.97M | 247.2M | 71.68M | 24.93M | 66.51M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 20.47M | 8.32M | 8.31M | 10.29M |
| Total Current Assets | 558.1M | 444.44M | 213.52M | 160.81M | 148.68M |
| Property, Plant & Equipment (Net) | 161.78M | 159.4M | 145.59M | 135.27M | 65.22M |
| Goodwill | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M |
| Intangible Assets | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M |
| Long-term Investments | 195.88M | 10.05M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 13.82M | 9.01M | 6.37M | 5.12M | 3.17M |
| Total Non-current Assets | 571.31M | 378.28M | 351.78M | 340.21M | 268.21M |
| Total Assets | 1.13B | 822.72M | 565.3M | 501.02M | 416.89M |
| Account Payables | 2.22M | 2.86M | 4.11M | 5.21M | 1.67M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 74.63M | 76.59M | 23.46M | 300K | 51.93M |
| Total Current Liabilities | 99.24M | 111.5M | 64.49M | 45.43M | 78.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 199.89M | 116.04M | 122.41M | 123.42M | 113.36M |
| Total Non-current Liabilities | 301.67M | 211.9M | 213.31M | 205.08M | 177.28M |
| Total Liabilities | 400.91M | 323.41M | 277.79M | 250.52M | 256.01M |
| Common Stock | 18K | 19K | 20K | 22K | 27K |
| Retained Earnings | (785.36M) | (1.05B) | (1.34B) | (1.6B) | (1.85B) |
| Accumulated OCI | (1.37M) | (4.33M) | (60K) | 14K | 28K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 728.5M | 499.32M | 287.51M | 250.5M | 160.88M |
| Total Debt | 110.94M | 108.25M | 104.1M | 94.2M | 78.86M |
| Net Debt | (142.09M) | (68.51M) | (29.42M) | (33.37M) | 6.99M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.